^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

BCL2 expression

i
Other names: BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
Entrez ID:
1d
Anticancer Potential of Postbiotic Derived from Lactobacillus brevis and Lactobacillus casei: In vitro Analysis of Breast Cancer Cell Line. (PubMed, Probiotics Antimicrob Proteins)
These CFSs may serve as adjunctive medications for suppressing the proliferation of cancer cells. The results of the current study highlight the potential of postbiotics in cancer treatment and suggest that supernatants may serve as effective agents for suppressing cancer cell growth and viability.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CSF2 (Colony stimulating factor 2) • CASP9 (Caspase 9)
|
BCL2 expression • BAX expression
1d
Protective effect of luteolin against oxidative stress‑mediated cell injury via enhancing antioxidant systems. (PubMed, Mol Med Rep)
Moreover, luteolin enhanced the activity and protein expressions of superoxide dismutase, catalase, glutathione peroxidase, and heme oxygenase‑1. Overall, these results indicated that luteolin inhibits H2O2‑mediated cellular damage by upregulating antioxidant enzymes.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • HMOX1 (Heme Oxygenase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • CAT (Catalase)
|
BCL2 expression • BAX expression • HMOX1 expression
1d
Ptehosides A-I: nine undescribed iridoids with in vitro cytotoxicity from the whole plant of Pterocephalus hookeri (C.B. Clarke) Höeck. (PubMed, Phytochemistry)
As result, compound 9 exhibited substantial inhibitory activity on Caco2, Huh-7, and SW982 cells with IC50 values of 1.17 ± 0.05, 1.15 ± 0.05 and 1.14 ± 0.04 μM, respectively. A preliminary mechanism study showed that 9 arrested the cell cycle of SW982 cells in the G0/G1 phase and induced apoptosis by upregulating Bax expression and downregulating Bcl-2 expression.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
1d
Bcl-2 dependent modulation of Hippo pathway in cancer cells. (PubMed, Cell Commun Signal)
We discovered that Bcl-2 regulates the Hippo pathway in different tumor types, promoting cell migration, adaptation to higher stiffness culture condition and fibroblast activation. Our data indicate that Bcl-2 inhibitors should be further investigated to counteract cancer-promoting mechanisms.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1)
|
BCL2 overexpression • BCL2 expression
2d
CD4+CD57+ senescent T cells as promoters of systemic lupus erythematosus pathogenesis and the therapeutic potential of senolytic BCL-2 inhibitor. (PubMed, Eur J Immunol)
Further, treatment with ABT-263 (a senolytic BCL-2 inhibitor) in MRL/lpr mice resulted in decreased: (1) frequency of CD4+CD44hiCD62L-PD-1+CD153+ senescent CD4+ T cells; (2) frequency of CD19+CD11c+T-bet+ age-related B cells; (3) level of serum antinuclear antibody; (4) proteinuria; (5) frequency of Tfh cells; and (6) renal histopathological abnormalities. Collectively, these results indicated a dominant role for CD4+CD57+ senescent CD4+ T cells in the pathogenesis of SLE and senolytic BCL-2 inhibitor ABT-263 may be the potential treatment in ameliorating lupus phenotypes.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • IL15 (Interleukin 15) • ITGAX (Integrin Subunit Alpha X) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
|
BCL2 expression
|
navitoclax (ABT 263)
2d
Small Molecule Functional Converter of B-Cell Lymphoma-2 (Bcl-2) Suppresses Breast Cancer Lung Metastasis. (PubMed, ACS Pharmacol Transl Sci)
BFC1103 has the potential for further optimization and development for clinical testing in metastatic cancers that express Bcl-2. This study demonstrates a new approach to target Bcl-2 using a small molecule, BFC1103, to suppress metastatic disease.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 overexpression • BCL2 expression
2d
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P3, N=302, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
Trial completion date • Trial primary completion date • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • TNFA (Tumor Necrosis Factor-Alpha) • CARD11 (Caspase Recruitment Domain Family Member 11) • TNFAIP3 (TNF Alpha Induced Protein 3) • CD79A (CD79a Molecule) • GSTT1 (Glutathione S-transferase theta 1)
|
BCL2 expression • MYC expression • MYC translocation • CD79A mutation • CD79A mutation + CD79B mutation
|
Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate)
3d
Investigating the effect of LncRNA DLGAP1-AS2 suppression on chemosensitivity of gastric cancer to chemotherapy. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
However, it reduced the stemness feature, the rate of cell viability, proliferation, and metastasis compared to the effect of each treatment alone; the results also showed the arrest of the cell cycle in the Sub G1 phase after the combined treatment and a further reduction in the number and size of the formed colonies. Suppressing the expression of lncRNA DLGAP1-AS2 by siRNA followed by treatment with oxaliplatin can be utilized as an effective and new therapeutic technique for gastric cancer therapy.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • ANXA5 (Annexin A5) • DLGAP1-AS2 (DLGAP1 Antisense RNA 2)
|
BCL2 expression • TP53 expression • BAX expression
|
oxaliplatin
3d
SPINK4 modulates inhibition of glycolysis against colorectal cancer progression. (PubMed, Biomol Biomed)
Besides, SPINK4 overexpression altered glycolytic activity, reduced 2-Deoxy-D-glucose (2-DG) absorption, and controlled critical glycolytic enzymes, resulting in alterations in metabolic pathways, whereas SPINK4 knockdown reversed this effect...Moreover, high expression of SPINK4, hexokinase 2 (HK2), glucose transporter 1 (GLUT1), lactate dehydrogenase A (LDHA), and pyruvate kinase M2 (PKM2) was observed in CRC tissues. As a key inhibitor of glycolytic metabolism in CRC, SPINK4 promises metabolic intervention in CRC therapy due to its impact on tumor growth and cell proliferation.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • LDHA (Lactate dehydrogenase A) • HK2 (Hexokinase 2) • PKM (Pyruvate Kinase M1/2) • SLC2A1 (Solute Carrier Family 2 Member 1)
|
BCL2 expression
3d
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
|
Venclexta (venetoclax)
3d
Recombinant Klotho protein protects pulmonary alveolar epithelial cells against sepsis-induced apoptosis by inhibiting the Bcl-2/Bax/caspase-3 pathway. (PubMed, Adv Clin Exp Med)
This study demonstrated that Klotho can ameliorate acute lung injury (ALI) induced by sepsis by inhibiting inflammatory responses and exerting anti-apoptotic effects by suppressing Bcl-2/Bax/caspase-3 pathway activation.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta)
|
BCL2 expression • BAX expression • IL6 expression
4d
The RTK-RAS signaling pathway is enriched in patients with rare acute myeloid leukemia harboring t(16;21)(p11;q22)/FUS::ERG. (PubMed, Blood Sci)
Transcriptome analysis revealed enrichment of the phosphatidylinositol-3-kinase-Akt (PI3K-Akt), mitogen-activated protein kinase (MAPK), and RAS signaling pathways and upregulation of BCL2, the target of venetoclax, in FUS::ERG AML compared to RUNX1::RUNX1T1 AML, a more common AML subtype with good prognosis...Allogeneic hematopoietic stem cell transplantation failed to improve outcomes. Overall, the high incidence of RTK-RAS pathway mutations and high expression of BCL2 may indicate promising therapeutic targets in this high-risk AML subset.
Journal • IO biomarker
|
NRAS (Neuroblastoma RAS viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • RUNX1 (RUNX Family Transcription Factor 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • NCAM1 (Neural cell adhesion molecule 1) • FUS (FUS RNA Binding Protein)
|
KRAS mutation • RAS mutation • BCL2 overexpression • BCL2 expression • NCAM1 positive
|
Venclexta (venetoclax)
6d
Intestinal metabolite xylulose inhibits colorectal cancer by inducing apoptosis through the MAPK signalling pathway. (PubMed, Toxicol Appl Pharmacol)
Xylulose inhibits CRC growth by inducing apoptosis through attenuation of the MAPK signalling pathway. These results suggest that xylulose may serve as an effective agent for CRC therapy.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP3 (Caspase 3)
|
BCL2 expression
7d
Evaluation of the cytotoxic activities of the essential oil from Pistacia atlantica Desf. oleoresin on human gastric cancer cell lines. (PubMed, Med Oncol)
The findings of this study offer evidence supporting the cytotoxic effects of PAEO on gastric cancer cell lines by promoting apoptosis. The findings suggest that PAEO may offer potential as a therapeutic candidate in managing and treating gastric cancer.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
7d
Hyaluronic acid-coated liposomes for enhanced in vivo efficacy of neogambogic acid via active tumor cell targeting and prolonged systemic exposure. (PubMed, J Liposome Res)
Meanwhile, HA-NGA-L increased the AUC and t1/2 by 5.34-fold and 3.94-fold, respectively. In summary, the present study shows that HA-NGA-L may be safe and effective for the tumor-targeted delivery of neogambogic acid.
Preclinical • Journal • IO biomarker • Tumor cell
|
BCL2 (B-cell CLL/lymphoma 2) • CD44 (CD44 Molecule) • CASP3 (Caspase 3)
|
BCL2 expression • CD44 expression • CD44 underexpression
7d
Berberis vulgaris L. Root Extract as a Multi-Target Chemopreventive Agent against Colon Cancer Causing Apoptosis in Human Colon Adenocarcinoma Cell Lines. (PubMed, Int J Mol Sci)
The chemical composition of BVR was determined using a UHPLC-UV-CAD-MS/MS analysis and confirmed the presence of several known alkaloids, including berberine, as well as other alkaloids and two derivatives of hydroxycinnamic acid (ferulic and sinapic acid hexosides). The results are very promising and encourage the use of BVR as a comprehensive chemopreventive agent (anti-inflammatory, antioxidant, and pro-apoptotic) in colorectal cancer, and were widely discussed alongside data from the literature.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • CASP3 (Caspase 3) • BCL2L2 (BCL2 Like 2) • CASP9 (Caspase 9)
|
BCL2 expression
7d
Tris(1,3-dichloro-2-propyl) phosphate-induced cytotoxicity and its associated mechanisms in human A549 cells. (PubMed, Toxicol Ind Health)
In addition, cell apoptosis was induced via altering the expression levels of Bcl-2, BAX, and BAK. Our study implies that TDCIPP may pose potential health risks to the human respiratory system and its toxicity should not be neglected.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • BAX (BCL2-associated X protein) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BCL2 expression • CCND1 expression • BAX expression • CDK6 expression • CDKN1B expression
7d
LncRNA NUTM2A-AS1 silencing inhibits glioma via miR-376a-3p/YAP1 axis. (PubMed, Cell Div)
In addition, lncRNA NUTM2A-AS1 positively regulated of YAP1 expression in glioma cells. In conclusion, silencing of lncRNA NUTM2A-AS1 inhibited proliferation and induced apoptosis in human glioma cells via the miR-376a-3p/YAP1 axis.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • YAP1 (Yes associated protein 1) • BAX (BCL2-associated X protein) • NUTM2A (NUT Family Member 2A)
|
BCL2 expression
7d
Synthesis of novel indol-3-acetamido analogues as potent anticancer agents, biological evaluation and molecular modeling studies. (PubMed, Bioorg Chem)
To rationalize the observed biological activities of 17, our study also included a comprehensive analysis using molecular docking and MD simulations. This integrative approach revealed that 17 fits tightly into the active site of the CB2 receptor and is involved in key interactions that may be responsible for its anti-proliferative effects.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP7 (Caspase 7) • ANXA5 (Annexin A5)
|
BCL2 expression • TP53 expression • BAX expression
8d
The protective role of resveratrol against high glucose-induced oxidative stress and apoptosis in HepG2 cells. (PubMed, Food Sci Nutr)
Our results demonstrate that resveratrol provides protection against oxidative stress and apoptosis induced by high glucose in HepG2 cells. Hence, resveratrol shows potential as an effective approach to address the impaired antioxidant response resulting from elevated glucose levels commonly observed in diabetes and metabolic disorders.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • NQO1 (NAD(P)H dehydrogenase, quinone 1) • CAT (Catalase)
|
BCL2 expression
10d
Apoptosis Pathway-Associated Proteins Are Frequently Expressed in Melanoma: A Study of 32 Cases With Focus on Acral Lentiginous Melanoma. (PubMed, Am J Dermatopathol)
In summary, ALM and NALM demonstrate frequent expressions of apoptosis-related proteins BCL2, MCL1, and BIM. Our findings suggest that patients with melanoma, including ALM, may be potential candidates for apoptosis-directed therapies.
Journal • IO biomarker
|
BRAF (B-raf proto-oncogene) • BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1)
|
BRAF V600E • BRAF V600 • BCL2 expression • MCL1 expression
10d
Effect of Raltitrexed on ECA109 Cellular Radiosensitivity and Its Mechanism in Esophageal Cancer. (PubMed, Curr Pharm Des)
Raltitrexed can inhibit the growth of esophageal cancer ECA109 cells and has a radiosensitization effect.
Journal • IO biomarker
|
BAX (BCL2-associated X protein)
|
BCL2 expression
|
Tomudex (raltitrexed)
11d
Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status. (PubMed, Blood Adv)
Because continuous inhibition of BCL-XL causes thrombocytopenia, we proposed and tested an interrupted 4 days ON / 3 days OFF treatment regimen, which retained the desired anti-tumor synergy with manageable platelet toxicity. The proposed VEN and A1155463 combination represents an innovative chemotherapy-free regimen with significant preclinical activity across diverse BCL2-positive hematologic malignancies irrespective of the BCL1L11/BIM status.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • BCL2L11 (BCL2 Like 11)
|
BCL2 expression • BCL2 positive • BCL2L11 deletion
|
Venclexta (venetoclax)
12d
Protective role of fruits of Rosa odorata var. gigantea against WIRS-induced gastric mucosal injury in rats by modulating pathway related to inflammation, oxidative stress and apoptosis. (PubMed, Chin Herb Med)
The current work demonstrated that FOE exerted a gastroprotective activity against gastric mucosal injury induced by WIRS. The underlying mechanism might be associated with the improvement of anti-inflammatory, anti-oxidation and anti-apoptosis systems.
Preclinical • Journal • PARP Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PCNA (Proliferating cell nuclear antigen) • GAST (Gastrin 2) • IL1B (Interleukin 1, beta) • CAT (Catalase)
|
BCL2 expression • BAX expression
12d
Pleiotropic attenuating effect of Ginkgo biloba against isoprenaline-induced myocardial infarction via improving Bcl-2/mTOR/ERK1/2/Na+, K+-ATPase activities. (PubMed, Chin Herb Med)
The expression of Bcl-2, ERK1/2 and mTOR was increased while the histomorphological alterations were reversed. The cardioprotective effects of GBE may be due to a mechanism involving increased Bcl-2/mTOR/ERK1/2/Na+, K+-ATPase activity.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • mTOR (Mechanistic target of rapamycin kinase) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CAT (Catalase)
|
BCL2 expression • IL6 expression
13d
Study on the inhibitory and pro-apoptotic effects of different concentrations of total tanshinone alone and in combination with tyrosine kinase inhibitors on human myeloid leukemia cell lines (PubMed, Zhonghua Yi Xue Za Zhi)
When combined with 0.25 μmol/L imatinib, 8.75 μg/ml total tanshinone could enhance the induction of apoptosis effects on K562 and K562/T315I cell lines...Total tanshinone inhibited the proliferation-related signaling pathway and DNA damage repair pathway of myeloid leukemia cell lines, and activated the signaling pathway that induces apoptosis in leukemia cells. Different concentrations of total tanshinoneinhibites proliferation and promote apoptosis in K562, Kasumi-1 and TKIs-resistant K562/T315I cell lines, and further enhance the anti-leukemic effect when combined with TKIs.
Preclinical • Journal • Combination therapy • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression • BCL2/BAX ratio elevation
|
imatinib
14d
The effect of LINC9137 targeting miR-140-3p-NKAIN3 signal axis on the development of goose testis sertoli cells. (PubMed, Poult Sci)
Meanwhile, this study co transfected overexpressed LINC9137 and miR-140-3p plasmids into sertoli cells, and found that the effect of LINC9137 overexpression on supporting cell proliferation was weakened by miR-140-3p. This study elucidates the role and function of the LINC9137 miR-140-3p-NKAIN3 signaling axis in the development of goose testes and spermatogenesis, establishes a regulatory network related to spermatogenesis, and provides a theoretical basis for studying the genetic regulation of goose spermatogenesis.
Journal • IO biomarker
|
MIR140 (MicroRNA 140)
|
BCL2 expression • BAX expression
15d
Therapeutic Potential of Silymarin in Mitigating Paclitaxel-Induced Hepatotoxicity and Nephrotoxicity: Insights into Oxidative Stress, Inflammation, and Apoptosis in Rats. (PubMed, Balkan Med J)
SIL administration reduced NF-κB, caspase-3, and IL-6 expression while increasing Bcl-2 and AQP2 levels in liver and kidney tissues of rats treated with SIL and PAX (p < 0.05). Our findings indicate the potential of SIL to alleviate PAX-induced liver and kidney damage in rats by reducing oxidative stress, inflammation, and apoptotic processes.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • CASP3 (Caspase 3) • CAT (Catalase) • CRP (C-reactive protein)
|
BCL2 expression • IL6 expression
|
paclitaxel
15d
Pharmacological p38 MAPK inhibitor SB203580 enhances AML stem cell line KG1a chemosensitivity to daunorubicin by promoting late apoptosis, cell growth arrest in S-phase, and miR-328-3p upregulation. (PubMed, Saudi Pharm J)
Remarkably, the enhanced KG1a cell sensitivity to DNR after SB203580 pretreatment was associated with an increased upregulation of miR-328-3p and slight downregulation of miR-26b-5p, compared to DNR effect. Altogether, these findings could contribute to the development of a new therapeutic strategy by targeting the p38 MAPK pathway to improve treatment outcomes in patients with refractory or relapsed AML.
Preclinical • Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • CASP7 (Caspase 7) • MIR328 (MicroRNA 328) • CCNB1 (Cyclin B1)
|
BCL2 expression • TP53 expression
|
daunorubicin
16d
Apoptotic effect of 5-fluorouracil-doxorubicin combination on colorectal cancer cell monolayers and spheroids. (PubMed, Mol Biol Rep)
The results indicated that the 5-FU + DOX combination therapy induces apoptosis and renders 5-FU and DOX more effective at lower concentrations compared to their alone use. This study reveals promising results in reducing the potential side effects of treatment by enabling the use of lower drug doses.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
|
5-fluorouracil • doxorubicin hydrochloride
16d
Synthesized Gold Nanoparticles with Moringa Oleifera leaf Extract Induce Mitotic Arrest (G2/M phase) and Apoptosis in Dalton's Lymphoma Cells. (PubMed, Cell Biochem Biophys)
Additionally, apoptosis induction was evidenced by Annexin V Staining, accompanied by modulation of apoptosis-related genes including decreased Bcl-2 expression and increased expression of Bax, Cyt-c, and Caspase-3 at both the mRNA and protein levels. Collectively, our findings underscore the promising anti-cancer properties of MLE-AuNPs, advocating their potential as a novel therapeutic avenue for Dalton's lymphoma.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • ANXA5 (Annexin A5) • CCNB1 (Cyclin B1)
|
BCL2 expression • BAX expression
16d
Combining the pharmaceutical and toxicological properties of select essential oils with their chemical components by GC-MS analysis. (PubMed, Chem Biodivers)
citrodora, O. vulgare, and R. officinalis EOs were found the most potent anticancer, as also witnessed by their higher modulatory effects on the gene expression of BAX and Bcl-2. Collectively, the present data highlight the importance to implement the knowledge and to valorise the chain of aromatic plants.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
17d
Identification and function analysis of BCL2 in immune response of Pteria Penguin. (PubMed, Fish Shellfish Immunol)
Furthermore, PpBCL2 silencing significantly inhibited antimicrobial activity of hemolymph supernatant by 1.4-fold, and significantly reduced the survival rate by 51.7% at 72 h post infection in P. penguin. These data indicated that PpBCL2 played an important role in immune response of P. penguin against V. parahaemolyticus infection.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
17d
Antitumor effects of polydopamine coated hydroxyapatite nanoparticles and its mechanism: Mitochondria-targeted ROS and calcium channels. (PubMed, Biomater Adv)
Further investigation revealed that the oxidative stress induced by PDA results in a large Reactive Oxygen Species (ROS) accumulation, thus triggering the mitochondria-dependent apoptosis pathway ROS-JNK/MAPK and inducing the cascade reaction of inhibiting the anti-apoptosis protein-Bcl-2 expression and activating the expression of the critical genes in apoptosis signaling pathway (caspase 3 and caspase 9). Besides, the significant increase of intracellular &lsqb;Ca2+] may also be an essential reason for the damage of mitochondria, eventually leading to apoptosis.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
BCL2 expression
18d
In Vitro Effects of Boric Acid on Cell Cycle, Apoptosis, and miRNAs in Medullary Thyroid Cancer Cells. (PubMed, Biol Trace Elem Res)
Our study suggests that boric acid may have anticancer activity in MTC by modulating apoptotic pathways. These findings suggest that boric acid could be a potential therapeutic agent for MTC and possibly for other malignancies with similar pathogenic mechanisms.
Preclinical • Journal • IO biomarker
|
BCL2L1 (BCL2-like 1) • MIR21 (MicroRNA 21) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1) • APAF1 (Apoptotic peptidase activating factor 1)
|
BCL2 expression
19d
Clinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
19d
A recombinant plasmid encoding human hepatocyte growth factor promotes healing of combined radiation-trauma skin injury involved in regulating Nrf2 pathway in mice. (PubMed, J Radiat Res)
In conclusion, the protective effect of pHGF may be related to inhibiting apoptosis and inflammation involving by upregulating Nrf2. Local pHGF injection distinctly promoted the healing of combined radiation-trauma injury and demonstrates potential as a gene therapy intervention for combined radiation-trauma injury in clinic.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • HGF (Hepatocyte growth factor) • TNFA (Tumor Necrosis Factor-Alpha) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • BAX (BCL2-associated X protein) • IL1B (Interleukin 1, beta)
|
BCL2 expression • BAX expression
19d
Assessment of the in Vitro Effects of Folate Core-Shell Conjugated Iron Oxide Nanoparticles as a Potential Agent for Acute Leukemia Treatment. (PubMed, Front Biosci (Landmark Ed))
Our study documents the successful synthetization and characterization of iron oxide, which has excellent anticancer activities. A metal oxide conjugation with the nanoparticles' core-shell enhanced the effect against acute leukemia.
Preclinical • Journal • IO biomarker
|
BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
|
doxorubicin hydrochloride
19d
Investigating the therapeutic potential of Bifidobacterium breve and Lactobacillus rhamnosus postbiotics through apoptosis induction in colorectal HT-29 cancer cells. (PubMed, Iran J Microbiol)
Additionally, B. breve postbiotics could inhibit metastasis through upregulation of RSPO2 while downregulating NGF and MMP7 expression in HT-29 cells. Our research suggests that postbiotic metabolites may be effective biological products for the prevention and treatment of cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • RSPO2 (R-Spondin 2) • MMP7 (Matrix metallopeptidase 7)
|
BCL2 expression • BAX expression
19d
The Effect of Tumor Resection and Radiotherapy on the Expression of Stem Cell Markers (CD44 and CD133) in Patients with Squamous Cell Carcinoma. (PubMed, Int J Hematol Oncol Stem Cell Res)
mRNA expression level of Bcl-2 and ALDH was increased, but Bax and Bak gene expressions were reduced significantly The results also indicated that the expression of CD44 significantly decreased after tumor resection and radiotherapy. The upregulation of mRNA level of Bcl-2 and ALDH, and the downregulation of Bax and Bak gene expression were noted in these cases when compared to the healthy control group.
Journal • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD44 (CD44 Molecule) • BAX (BCL2-associated X protein) • BAK1 (BCL2 Antagonist/Killer 1)
|
BCL2 expression • CD44 expression • BAX expression • CD133 expression
19d
Effect of Resveratrol on MMP-2 Expression in Scleral Fibroblasts: An In Vitro Study. (PubMed, Curr Eye Res)
Flow cytometry showed that the cell apoptosis rate was significantly lower in HFSFs treated with Res. In conclusion, these findings suggest that Res increases COL1A1 expression while inhibiting MMP-2 and cell apoptosis in HFSFs, possibly through modulation of the JAK2/STAT3 signaling pathway.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MMP2 (Matrix metallopeptidase 2) • COL1A1 (Collagen Type I Alpha 1 Chain)
|
BCL2 expression
20d
Sequence-dependent effects of hematoporphyrin derivatives (HPD) photodynamic therapy and cisplatin on lung adenocarcinoma cells. (PubMed, Photodiagnosis Photodyn Ther)
The order of the combination therapy (PDT + DDP / DDP + PDT) was important. The HPD-PDT followed by DDP significantly inhibited LUAD cell viability, which may be related to the mitochondrial apoptotic pathway.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP9 (Caspase 9) • ANXA5 (Annexin A5)
|
BCL2 expression • BAX expression
|
cisplatin